Table 2.
Change in lipid profiles, AI, mFRS, and IR in patients receiving biologic or biologic-naïve therapy
| Adalimumab (n = 32) | Etanercept (n = 16) | Tocilizumab (n = 24) | Without biologic (n = 20) | |
|---|---|---|---|---|
| Total cholesterol, mg/dL | ||||
| Baseline | 212.3 ± 5.8 | 195.3 ± 9.8 | 191.8 ± 5.3 | 209.6 ± 11.2 |
| Week 24 | 212.1 ± 5.6 | 191.0 ± 7.9 | 211.5 ± 6.8* | 199.5 ± 8.6 |
| HDL-C, mg/dL | ||||
| Baseline | 73.0 ± 2.7 | 67.5 ± 4.1 | 67.7 ± 3.3 | 70.4 ± 4.4 |
| Week 24 | 77.1 ± 3.8 | 71.7 ± 4.0 | 72.1 ± 4.0 | 70.8 ± 5.2 |
| LDL-C, mg/dL | ||||
| Baseline | 131.3 ± 5.3 | 118.4 ± 8.9 | 119.2 ± 5.5 | 123.4 ± 9.1 |
| Week 24 | 127.0 ± 5.6 | 117.0 ± 7.4 | 134.3 ± 6.5* | 114.2 ± 6.0 |
| Triglyceride, mg/dL | ||||
| Baseline | 105.6 ± 8.3 | 129.8 ± 21.1 | 118.8 ± 9.8 | 86.9 ± 9.3 |
| Week 24 | 105.7 ± 7.1 | 106.4 ± 12.0 | 135.5 ± 11.4* | 88.9 ± 9.6 |
| Atherogenic index | ||||
| Baseline | 3.00 ± 0.11 | 3.05 ± 0.29 | 2.94 ± 0.12 | 3.11 ± 0.18 |
| Week 24 | 2.91 ± 0.14 | 2.75 ± 0.16 | 3.11 ± 0.16 | 3.01 ± 0.20 |
| Modified FRS | ||||
| Baseline | 3.52 ± 0.65 | 4.22 ± 1.44 | 3.48 ± 0.91 | 3.43 ± 0.93 |
| Week 24 | 3.42 ± 0.72 | 4.22 ± 1.40 | 4.04 ± 0.97* | 3.25 ± 0.79 |
| Insulin resistance | ||||
| Baseline | 2.75 ± 0.29 | 2.90 ± 0.53 | 2.97 ± 0.38 | 2.28 ± 0.34 |
| Week 24 | 1.76 ± 0.39* | 1.71 ± 0.26** | 1.99 ± 0.25** | 1.77 ± 0.18 |
Data are presented as mean ± standard error of mean. *P <0.05, **P <0.005, versus before treatment, determined by Wilcoxon signed rank test. FRS, Framingham risk score; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.